Home/Biosimilar Atlas/Epoetin alfa and zeta/Binocrit / Epoetin alfa Hexal / Abseamed

Binocrit / Epoetin alfa Hexal / Abseamed

Epoetin alfa and zeta biosimilar developed by Sandoz, development code HX575. Reference product Eprex (Epogen and Procrit in the United States).

Brands by market: Binocrit (EU, UAE); Epoetin alfa Hexal and Abseamed (EU) · Commercial partner or holder: Sandoz; Hexal; Medice (EU brands)
FDAnot listed
EMAAug 2007authorised
PMDAnot listed
HCnot listed
CDSCOnot listed
EDESep 2018registered

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union · Binocrit

European Medicines Agency and European CommissionApproved
Brand
Binocrit
Holder or applicant
Sandoz GmbH
Pathway
Centralised (Article 10(4))
Approved
Aug 2007
Application or permission
EMEA/H/C/000725
Indications as licensed
Anaemia of CKD, chemotherapy-induced anaemia, autologous blood predonation, elective surgery
Presentations
see SmPC
Note
First EU epoetin biosimilar.
Source
S017
EMA

European Union · Epoetin alfa Hexal

European Medicines Agency and European CommissionApproved
Brand
Epoetin alfa Hexal
Holder or applicant
Hexal AG
Pathway
Centralised (Article 10(4))
Approved
Aug 2007
Application or permission
EMEA/H/C/000726
Presentations
see SmPC
Note
Duplicate authorisation.
Source
S017
EMA

European Union · Abseamed

European Medicines Agency and European CommissionApproved
Brand
Abseamed
Holder or applicant
Medice Arzneimittel Pütter GmbH Co. KG
Pathway
Centralised (Article 10(4))
Approved
Aug 2007
Application or permission
EMEA/H/C/000727
Presentations
see SmPC
Note
Duplicate authorisation.
Source
S017
PMDA

Japan

Not listed by PMDA.

HC

Canada

Not listed by HC.

CDSCO

India

Not listed by CDSCO.

EDE

United Arab Emirates · Binocrit

Emirates Drug EstablishmentRegistered
Brand
Binocrit
Holder or applicant
Sandoz GmbH TechOps, Austria · UAE supplier Alphamed Drug Store
Pathway
Registered medical product
Registered
Sep 2018
Presentations
1,000 IU/0.5 mL to 40,000 IU/mL PFS
Source
S018

Chronology

Sources

All epoetin alfa and zeta biosimilars

Planning epoetin alfa and zeta biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.